FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Cipla Budesonide Inhalation Suspension Recall

Budesonide Inhalation Suspension, 0

Cipla USA, Inc. · Warren, NJ

Risk level
Class II
Reported by FDA
Jul 30, 2025
Recall ID
D-0541-2025
Check your lot numberHow we source this data

Summary

Cipla recalled Budesonide Inhalation Suspension starting Jun 30, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0541-2025 on Jul 30, 2025. Reason: Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule. Status: Ongoing.

Why it was recalled

Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.

Product description

Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only, Manufactured by: Cipla Ltd. Indore SEZ, Pithampur, India. Manufactured for: Ciple USA, Inc. 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC# 69097-319-86 (pouch), 69097-319-87 (carton)

Lot numbers, UPCs & expiration codes

Batch # 4IA0505, Exp 09/31/2026

Where it was sold

Distributed Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0541-2025
Classification
Class II
Status
Ongoing
Recall initiated
Jun 30, 2025
FDA report date
Jul 30, 2025
Quantity
13,680 ampoules
Recall type
Voluntary: Firm initiated
Recalling firm
Cipla USA, Inc.

Original FDA data

Every field from FDA enforcement report D-0541-2025, exactly as published.

Show all FDA fields
City
Warren
State
NJ
Status
Ongoing
Country
United States
Event ID
97170
Address
10 Independence Blvd
Code information
Batch # 4IA0505, Exp 09/31/2026
Postal code
07059-2730
Report date
Jul 30, 2025
Product type
Drugs
Recall number
D-0541-2025
Classification
Class II
Recalling firm
Cipla USA, Inc.
Product quantity
13,680 ampoules
Reason for recall
Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only, Manufactured by: Cipla Ltd. Indore SEZ, Pithampur, India. Manufactured for: Ciple USA, Inc. 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC# 69097-319-86 (pouch), 69097-319-87 (carton)
Distribution pattern
Distributed Nationwide in the USA
Recall initiation date
Jun 30, 2025
Initial firm notification
Letter
Center classification date
Jul 22, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0541-2025, published Jul 30, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls